OF SHARED RESOURCE The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Biostatistics Shared Resource (BiostatSR) consists of six doctoral-level faculty biostatisticians positions, one of which is in the process of being filled, four master's level statisticians, and two information technology specialists. BiostatSR members collaborate and consult with other Cancer Center investigators in the design, conduct, and analysis of cancer-related clinical, preclinical, laboratory, and epidemiologic investigations. BiostatSR also reviews proposals for cancer-related clinical investigations in the Protocol Review and Monitoring System-Clinical Research Review Committee (PRMS-CRC). The Biostatistics Core provides consultation and expertise regarding study design (including validity of the overall design, feasibility of meeting objectives, sample size and projection of study duration), recommendations for and development of key infrastructure (data management and computer systems support), data analysis, preparation of reports and assistance with manuscript writing, and development of new biostatistical methods if required by the project. The goal of the Biostatistics Core is to ensure that study designs, data monitoring, and analyses use state-of-the-art methods, and to help developmental studies supported by the Center garner peer-reviewed funding. This Core has experienced turnover in faculty during the grant cycle, most of whom have successfully been replaced, with a plan to undergo controlled growth during the next grant cycle amongst both faculty and staff. In addition to being strongly integrated into all Programs in the Center, biostatisticians in the Core have important intellectual ties to other professionals in the medical institutions who are engaged in similar activities in other disciplines. This diverse environment provides SKCCC investigators with strong, broad-based biostatistical expertise that is always accessible Plans for the future of Biostatistics include collaboration in initiatives in information systems to support clinical and basic science research data, and development of a centerwide Program in quantitative cancer research. Lay: This Core provides consultation and expertise regarding study design, recommendations for and development of key infrastructure, data analysis, preparation of reports and assistance with manuscript writing, and development of new biostatistical methods if required by the project. Cancer Center Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010 .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-49
Application #
8559533
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2012-08-09
Budget End
2013-04-30
Support Year
49
Fiscal Year
2012
Total Cost
$568,209
Indirect Cost
$217,463
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications